Polaryx Therapeutics will participate in the National Tay-Sachs & Allied Diseases Association Annual Family Conference from April 30 to May 3, 2026, to engage with patients and advocates. The company will share progress on its lead drug candidate, PLX-200, which targets multiple lysosomal storage disorders including Sandhoff disease, currently in a Phase 2 basket trial called SOTERIA. This trial aims to evaluate PLX-200's safety and efficacy across several rare pediatric diseases with no current standard treatments. Polaryx plans to start the trial in the second half of 2026, with sites in the US, Europe, and Asia, hoping to accelerate development of disease-modifying therapies for underserved patient populations.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
